EP 2534139 A1 20121219 - NOVEL AMINOALKYL-OXAZOLE AND AMINOALKYL-THIAZOLE CARBOXYLIC ACID AMIDES AS REGENERATION-PROMOTING SUBSTANCES FOR SENSORY ORGANS AND POST-MITOTIC TISSUE
Title (en)
NOVEL AMINOALKYL-OXAZOLE AND AMINOALKYL-THIAZOLE CARBOXYLIC ACID AMIDES AS REGENERATION-PROMOTING SUBSTANCES FOR SENSORY ORGANS AND POST-MITOTIC TISSUE
Title (de)
NEUE AMINOALKYL-OXAZOL- UND AMINOALKYL-THIAZOLCARBONSÄUREAMIDE ALS REGENERATIONSFÖRDERNDE SUBSTANZEN FÜR SINNESORGANE UND POSTMITOTISCHE GEWEBE
Title (fr)
NOUVEAUX AMIDES D'ACIDE AMINOALKYL-OXAZOLCARBOXYXLIQUE ET D'ACIDE AMINOALKYL-THIAZOLCARBOXYLIQUE COMME SUBSTANCES FAVORISANT LA RÉGÉNÉRATION POUR LES ORGANES SENSORIELS ET LES TISSUS POSTMITOTIQUES
Publication
Application
Priority
- DE 102010007281 A 20100208
- EP 2011000502 W 20110204
Abstract (en)
[origin: CA2789013A1] The present invention relates to novel aminoalkyl-oxazole and aminoalkyl-thiazole carboxylic acid amides that stimulate the endogenous regeneration of terminally differentiated cells in highly specialized organs, tissues and sensory epithelia in mammals in situ. The claimed low-molecular-weight compounds are able to induce corresponding cell biological changes such as dedifferentiation, proliferation and the subsequent terminal redifferentiation of cells of the normally post-mitotic tissue. The invention in particular relates to compounds with which a de novo formation of hair sensory cells in the organ of Corti can be obtained by inducing cell separation of supporting cells of the inner ear and hearing can be restored after hair cell loss. The compounds according to the invention for the first time enable a causal treatment of inner ear hardness of hearing caused, for example, by noise, ototoxic substances, symptoms of old age or genetic causes on the basis of regenerative biology. The invention further relates to methods for producing the compounds according to the invention, to the formulation (1) (2) thereof as pharmaceutical preparations and to the use thereof for producing pharmaceuticals for regenerative medicine.
IPC 8 full level
C07D 263/34 (2006.01); A61K 31/421 (2006.01); A61K 31/422 (2006.01); A61K 31/427 (2006.01); A61P 27/16 (2006.01); C07D 413/06 (2006.01); C07D 413/12 (2006.01); C07D 417/04 (2006.01); C07D 417/12 (2006.01)
CPC (source: EP US)
A61P 9/00 (2017.12 - EP); A61P 21/00 (2017.12 - EP); A61P 25/00 (2017.12 - EP); A61P 27/00 (2017.12 - EP); A61P 27/16 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07D 263/34 (2013.01 - EP US); C07D 413/06 (2013.01 - EP US); C07D 413/12 (2013.01 - EP US); C07D 417/04 (2013.01 - EP US); C07D 417/12 (2013.01 - EP US)
Citation (search report)
See references of WO 2011095338A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
DE 102010007281 A1 20110811; CA 2789013 A1 20110811; CN 102947281 A 20130227; CN 102947281 B 20151125; EP 2534139 A1 20121219; JP 2013518917 A 20130523; US 2013012514 A1 20130110; US 2014288135 A1 20140925; US 8889723 B2 20141118; WO 2011095338 A1 20110811
DOCDB simple family (application)
DE 102010007281 A 20100208; CA 2789013 A 20110204; CN 201180017156 A 20110204; EP 11703394 A 20110204; EP 2011000502 W 20110204; JP 2012552297 A 20110204; US 201113577503 A 20110204; US 201414208419 A 20140313